Journal article
Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer
Journal of oncology pharmacy practice, Vol.10(3), pp.169-175
09/2004
DOI: 10.1191/1078155204jp130oa
Abstract
Objective. Provide a review and update of gefitinib (Iressa®), including recent data on mutations in the epidermal growth factor receptor (EGFR) and possible implications in non-small cell lung cancer patients.
Data sources. Primary literature and review articles were researched using Pub-Med. Articles through June 2004 were considered for preparation of the review. All clinical trials with published results and articles reporting EGFR mutations were considered for inclusion by the authors.
Conclusions. Gefitinib is a novel EGFR tyrosine kinase inhibitor approved for treatment of chemo-resistant NSCLC. Response rates of 10-19% have been observed in clinical trials with no improvement when combined with chemotherapy. Currently, gefitinib is used as a single agent for advanced NSCLC that is resistant to chemotherapy. Mutations in EGFR correlating with response to gefitinib have recently been described. Based on these early results, genetic testing of NSCLC patients upon diagnosis could predict response to gefitinib. Early treatment of NSCLC patients positive for EGFR mutations with gefitinib remains to be tested.
Details
- Title: Subtitle
- Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer
- Creators
- Matt Palmer - University of Wisconsin–MadisonJustin Geurink - University of Wisconsin–MadisonKristine Hahn - University of Wisconsin–MadisonJill Kolesar - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.10(3), pp.169-175
- DOI
- 10.1191/1078155204jp130oa
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 09/2004
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696539402771
Metrics
1 Record Views